BSE filing, NSE: GLAXO. Summary written from the filing by ALFA Finder's alert engine.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,531.40
- Market cap
- ₹42,883 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 40.1×Sector 47.2×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Board Meeting Date
GlaxoSmithKline Pharmaceuticals Limited will hold a board meeting on 3rd November 2026 to consider and approve its unaudited financial results for the quarter ended 30th September 2026.
GlaxoSmithKline Pharmaceuticals Other Announcement
GlaxoSmithKline Pharmaceuticals Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI listing regulations.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GlaxoSmithKline Pharmaceuticals issued a corrigendum for its August 3, 2026, postal ballot notice, correcting a typographical error in a reported salary figure.
GlaxoSmithKline Pharmaceuticals Price Movement Clarification
GlaxoSmithKline Pharmaceuticals clarified that recent trading volume increases are purely market-driven. The company confirmed all material disclosures have been made according to SEBI regulations.
GlaxoSmithKline Pharmaceuticals Business Update
GlaxoSmithKline Pharmaceuticals received an income tax refund intimation of Rs 4.99 Crore for the assessment year 2025-2026.
- Value
- ₹4.99 Cr
Other board meeting outcome announcements
All →Cubical Financial Services Board Meeting Outcome
Cubical Financial Services' board approved establishing a new corporate office in North Delhi. No monetary amount or capacity is stated.
Atmastco Board Meeting Outcome
Atmastco Limited's board approved the notice of its 32nd AGM on 25 November 2026, the FY2025-26 Annual Report, a scrutinizer and e-voting arrangements. No material business decision or monetary amount is reported.
Indrayani Biotech Board Meeting Outcome
Indrayani Biotech appointed Ms. N. S. Poornima as Secretarial Auditor for FY 2025-26 to fill a casual vacancy. Company Secretary C.S. Shanmuga Sundar's resignation took effect on 2 November 2026.
Borana Weaves Board Meeting Outcome
Borana Weaves' board approved shifting its registered office to Surat, Gujarat, effective immediately. The change is an administrative address update with no business impact.
Emergent Industrial Solutions Board Meeting Outcome
Emergent Industrial Solutions reconstituted its four board committees, reassigning existing directors across Audit, Nomination, Stakeholders Relationship, and CSR roles. This is routine governance with no financial impact.
Winsol Engineers Board Meeting Outcome
Winsol Engineers' board approved AoA changes to allow voluntary dividend waiver and postal ballot logistics. All decisions are routine governance matters with no material business impact.